Skip to main content
Erschienen in: Infection 6/2011

01.12.2011 | Brief Report

The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria

verfasst von: F. G. De Rosa, N. Pagani, L. Fossati, S. Raviolo, C. Cometto, P. Cavallerio, C. Parlato, E. Guglielmi, R. Serra, G. Di Perri

Erschienen in: Infection | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective

To describe the impact of empiric appropriate treatment and the risk factors associated with mortality in patients with bacteremia by E. coli, K. pneumoniae and P. mirabilis producing ESBL.

Methods

Data were reviewed in an 8-year retrospective study, and 128 bacteremias were found: 80 caused by E. coli (62.5%), 28 by K. pneumoniae (21.9%) and 20 by P. mirabilis (18.6%).

Results

The initial antibiotic treatment, administered within 72 h after the first positive blood culture, was appropriate with carbapenems or other antimicrobial agents with documented in vitro sensitivity in 53.8 and 16% of patients, respectively. The overall mortality 21 days after diagnosis was 17.2%, and it was 14.9 and 35.2% for patients adequately and inadequately treated, respectively. At univariate analysis the p value for mortality with and without appropriate treatment was 0.05, and significant differences were found only for previous positive blood cultures (p = 0.004) and presence of septic shock at diagnosis (p = 0.006).

Conclusion

In this case series there was a high rate of initial appropriate empiric treatment, and only a marginal impact on mortality was found with regard to appropriate and inappropriate treatment. This report shows that the knowledge of ESBL-producing characteristics varies widely among the different case series for reasons that still have to be clarified.
Literatur
1.
Zurück zum Zitat Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–66.PubMedCrossRef Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–66.PubMedCrossRef
2.
Zurück zum Zitat Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39:333–40. (epub 2011 Jun 25).PubMedCrossRef Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39:333–40. (epub 2011 Jun 25).PubMedCrossRef
3.
Zurück zum Zitat Gona F, Mezzatesta ML, Corona D, Zerbo D, Scriffignano V, Stefani S, Veroux P, Veroux M. Klebsiella pneumoniae ESBL producers responsible for severe UTIs in a renal transplant unit. Infection. 2011;39:83–5. (epub 2011 Jan 25) PMID: 21264678.PubMedCrossRef Gona F, Mezzatesta ML, Corona D, Zerbo D, Scriffignano V, Stefani S, Veroux P, Veroux M. Klebsiella pneumoniae ESBL producers responsible for severe UTIs in a renal transplant unit. Infection. 2011;39:83–5. (epub 2011 Jan 25) PMID: 21264678.PubMedCrossRef
4.
Zurück zum Zitat Kuster SP, Hasse B, Huebner V, Bansal V, Zbinden R, Ruef C, Ledergerber B, Weber R. Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection. 2010;38:33–40. (epub 2010 Jan 27) PMID: 20108162.PubMedCrossRef Kuster SP, Hasse B, Huebner V, Bansal V, Zbinden R, Ruef C, Ledergerber B, Weber R. Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection. 2010;38:33–40. (epub 2010 Jan 27) PMID: 20108162.PubMedCrossRef
5.
Zurück zum Zitat Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, Arnan M, Marin M, Carratala J, Gudiol F. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65:333–41.PubMedCrossRef Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, Arnan M, Marin M, Carratala J, Gudiol F. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65:333–41.PubMedCrossRef
6.
Zurück zum Zitat Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31–7.PubMedCrossRef Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31–7.PubMedCrossRef
7.
Zurück zum Zitat Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D’Inzeo T, Fadda G, Cauda R, Spanu T. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51:1987–94.PubMedCrossRef Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D’Inzeo T, Fadda G, Cauda R, Spanu T. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51:1987–94.PubMedCrossRef
8.
Zurück zum Zitat Cohen-Nahum K, Saidel-Odes L, Riesenberg K, Schlaeffer F, Borer A. Urinary tract infections caused by multi-drug resistant Proteus mirabilis: risk factors and clinical outcomes. Infection. 2010;38:41–6. (epub 2009 Dec 7) PMID: 19998053.PubMedCrossRef Cohen-Nahum K, Saidel-Odes L, Riesenberg K, Schlaeffer F, Borer A. Urinary tract infections caused by multi-drug resistant Proteus mirabilis: risk factors and clinical outcomes. Infection. 2010;38:41–6. (epub 2009 Dec 7) PMID: 19998053.PubMedCrossRef
9.
Zurück zum Zitat Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, de Cueto M, Rios MJ, Hernandez JR, Pascual A. Bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis. 2006;43:1407–14.PubMedCrossRef Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, de Cueto M, Rios MJ, Hernandez JR, Pascual A. Bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis. 2006;43:1407–14.PubMedCrossRef
10.
Zurück zum Zitat Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, Mensa J. Analysis of 4,758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother. 2009;63:568–74.PubMedCrossRef Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, Mensa J. Analysis of 4,758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother. 2009;63:568–74.PubMedCrossRef
11.
Zurück zum Zitat Joo EJ, Kang CI, Ha YE, Park SY, Kang SJ, Wi YM, Lee NY, Chung DR, Peck KR, Song JH. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection. Infection. 2011;39:309–18. Joo EJ, Kang CI, Ha YE, Park SY, Kang SJ, Wi YM, Lee NY, Chung DR, Peck KR, Song JH. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection. Infection. 2011;39:309–18.
12.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef
13.
Zurück zum Zitat Venditti M, Falcone M, Corrao S, Licata G, Serra P. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med. 2009;150:19. W5.PubMed Venditti M, Falcone M, Corrao S, Licata G, Serra P. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med. 2009;150:19. W5.PubMed
14.
Zurück zum Zitat Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004;48:4574–81.PubMedCrossRef Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004;48:4574–81.PubMedCrossRef
15.
Zurück zum Zitat Kola A, Maciejewski O, Sohr D, Ziesing S, Gastmeier P. Clinical impact of infections caused by ESBL-producing E coli and K pneumoniae. Scand J Infect Dis. 2007;39:975–82.PubMedCrossRef Kola A, Maciejewski O, Sohr D, Ziesing S, Gastmeier P. Clinical impact of infections caused by ESBL-producing E coli and K pneumoniae. Scand J Infect Dis. 2007;39:975–82.PubMedCrossRef
16.
Zurück zum Zitat Yu VL. Guidelines for hospital-acquired pneumonia and health-care-associated pneumonia: a vulnerability, a pitfall, and a fatal flaw. Lancet Infect Dis. 2011;11:248–52.PubMedCrossRef Yu VL. Guidelines for hospital-acquired pneumonia and health-care-associated pneumonia: a vulnerability, a pitfall, and a fatal flaw. Lancet Infect Dis. 2011;11:248–52.PubMedCrossRef
17.
Zurück zum Zitat Tascini C, Malacarne P, Langer M, Menichetti F, Rossolini GM The 2011 revolution in antimicrobial susceptibility testing and reporting: what the ICU physicians need to know. Minerva Anestesiol. 2011. [Epub ahead of print]. Tascini C, Malacarne P, Langer M, Menichetti F, Rossolini GM The 2011 revolution in antimicrobial susceptibility testing and reporting: what the ICU physicians need to know. Minerva Anestesiol. 2011. [Epub ahead of print].
Metadaten
Titel
The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria
verfasst von
F. G. De Rosa
N. Pagani
L. Fossati
S. Raviolo
C. Cometto
P. Cavallerio
C. Parlato
E. Guglielmi
R. Serra
G. Di Perri
Publikationsdatum
01.12.2011
Verlag
Springer-Verlag
Erschienen in
Infection / Ausgabe 6/2011
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-011-0201-x

Weitere Artikel der Ausgabe 6/2011

Infection 6/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.